This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Rheumatoid Lung Disease류마티스폐질환

ICD-10M05.1
Synonyms / related termsRheumatoid arthritis–associated interstitial lung disease (RA-ILD), rheumatoid pleuritis, Caplan syndrome
Special Copayment ReductionV223 — severe intractable disease (10% copayment, 5 years)
Main age of onsetMainly occurs in seropositive RA patients in their 40s–60s, and in men

Contents

s1History
s2Causes
s3Genetics
s4General epidemiology
s5Pathophysiology
s6Symptoms
s7Signs
s8Screening
s9Diagnosis
s10Treatment
s11Prognosis
s12Prevention
s13References

1. History

Rheumatoid lung disease (RA-ILD) was recognized as an independent clinical entity in 1948 when Ellman and Ball first systematically described interstitial pneumonia in rheumatoid arthritis patients. Subsequently, in 1953, Caplan reported characteristic lung nodules in RA patients with pneumoconiosis and described 'Caplan syndrome'. In the 1960s–1970s, various forms of pulmonary involvement such as RA-associated pleuritis, lung nodules, and bronchiolitis were reported, and after the introduction of high-resolution CT (HRCT) in the 1980s, even clinically asymptomatic interstitial lung changes could be systematically evaluated. In the 2000s, classification of histologic patterns such as UIP (usual interstitial pneumonia), NSIP (nonspecific interstitial pneumonia), and OP (organizing pneumonia) was established through surgical lung biopsy and molecular biology techniques. After the introduction of methotrexate (MTX), it became known that MTX itself can cause pulmonary toxicity, so differentiating progressive ILD due to RA activity from drug-induced lung injury became a major clinical challenge. Since the 2010s, randomized controlled studies on RA-ILD treatment have been under way based on experience applying antifibrotic therapy (pirfenidone, nintedanib) to idiopathic pulmonary fibrosis, and in 2023 the results of the INBUILD study, which confirmed that nintedanib significantly reduces decline in lung function in autoimmune ILD including RA-ILD, began to be reflected in clinical guidelines.

2. Causes

The cause of RA-ILD is understood as a complex interaction of the systemic autoimmune abnormality of RA, environmental factors, and drug toxicity. The lung is proposed as a major trigger organ for the autoimmune response to citrullinated proteins, and evidence is accumulating that smoking promotes protein citrullination in lung epithelial cells and induces anti-CCP antibody production. Bacterial oral infection (especially peptidylarginine deiminase carried by Porphyromonas gingivalis) and abnormalities of the lung microbiome may also trigger pulmonary autoimmune responses. In terms of drug-induced lung injury, MTX is the most important and can cause both hypersensitivity pneumonitis and interstitial pneumonia. Pulmonary toxicity has also been reported with leflunomide, gold, penicillamine, and sulfasalazine. Cases of worsening interstitial lung disease after JAK inhibitor administration have been rarely reported, but a causal relationship is still unclear. Smoking, male sex, high anti-CCP antibody titer, high-titer seropositive RF, and the presence of extra-articular manifestations are established risk factors for ILD.

3. Genetics

The genetic basis of RA-ILD consists of the interaction between genetic risk factors of RA itself and genes determining predisposition to pulmonary fibrosis. HLA-DRB1*01 and *04 shared epitope alleles are associated not only with anti-CCP–positive RA but also with development of UIP-pattern RA-ILD. The MUC5B gene promoter polymorphism (rs35705950) is the strongest genetic risk factor for idiopathic pulmonary fibrosis and is also found at a significantly higher frequency in RA-ILD patients, suggesting that the RA-ILD UIP pattern and idiopathic pulmonary fibrosis share similar genetic pathways. TOLLIP (toll-interacting protein) gene polymorphisms and mutations in telomere-related genes TERT/TERC also increase the risk of developing RA-ILD. HLA-B54 has been reported to be associated with MTX pulmonary toxicity in East Asian populations. RA-ILD should be understood not as a simple complication of RA but as an endophenotype with its own genetic background, which is also why histologic pattern classification (UIP vs. NSIP vs. OP) is important in determining prognosis and treatment response.

4. General epidemiology

The prevalence of clinically significant ILD in RA patients is reported as about 5–10%, but reaches 30–40% when asymptomatic interstitial changes detectable by HRCT are included. RA-ILD occurs significantly more often in men, older age, long disease duration, seropositivity (high-titer RF/anti-CCP), and smokers. RA patients who smoke have an ILD risk about 2–3 times that of nonsmokers. In a Korean single-center study, the cumulative incidence of ILD in an RA cohort was reported as about 7–10% over 10 years. As radiographic patterns, UIP is the most common at about 50–60%, NSIP about 30%, and OP, DIP, etc. make up the rest. RA-ILD has a mortality 3–5 times higher than RA itself, and patients with a UIP pattern have significantly shorter median survival than those with an NSIP pattern (UIP: about 3–5 years, NSIP: about 7–9 years). ILD is one of the leading causes of death in RA patients, with the highest contribution after cardiovascular disease.

5. Pathophysiology

The pathophysiology of RA-ILD is understood in three stages: lung epithelial injury, autoimmune inflammation, and abnormal fibrotic repair. Anti-CCP antibodies against citrullinated vimentin, fibronectin, α-enolase, etc. in the lung epithelium bind to alveolar epithelial cells and induce complement activation and immune complex deposition. Activated dendritic cells and macrophages secrete IL-1β, TNF-α, and IL-6, and Th1/Th17 cell-mediated inflammation infiltrates the lung interstitium. TGF-β1 differentiates fibroblasts into myofibroblasts, and PDGF, FGF-2, and CTGF promote excessive collagen production, advancing irreversible fibrosis. Abnormal mucus secretion such as MUC5B impairs small airway clearance and promotes chronic bacterial colonization, contributing to persistent inflammation. Epithelial cell senescence due to telomere shortening is also emerging as an important mechanism of UIP pattern progression. MTX pulmonary toxicity results from a combination of T cell–mediated hypersensitivity reaction and alveolar injury due to antagonism of folate metabolism.

6. Symptoms

The most common early symptom of RA-ILD is slowly progressive exertional dyspnea, often accompanied by dry cough. Asymptomatic radiographic abnormalities often precede symptom onset by several years, making early diagnosis difficult. With progression, dyspnea at rest, cyanosis, weight loss, and fatigue appear, and in the end stage progression to respiratory failure occurs. The OP pattern may present with a subacute course with fever, cough, and chest pain, with a pneumonia-like clinical picture that does not respond to antibiotic treatment. Pleuritis and pleural effusion due to pleural involvement may accompany, and this is one of the most common pulmonary complications of RA. Caplan syndrome (RA with pneumoconiosis) shows a course of rapidly increasing lung nodules. MTX pulmonary toxicity presents acutely to subacutely with fever, cough, and dyspnea, sometimes with peripheral blood eosinophilia. When bronchiolitis is the main lesion, air trapping and airflow obstruction findings are prominent.

7. Signs

On lung auscultation, end-inspiratory fine crackles (Velcro rales) at the bases of both lungs are characteristic and prominent in the UIP pattern. In advanced cases, use of accessory respiratory muscles, paradoxical breathing, and cyanosis are observed. Clubbing occurs in about 20–30% of RA-ILD patients and is especially associated with the UIP pattern. Wheeze on auscultation may appear when bronchiolitis or reactive airway hyperresponsiveness is present. When pulmonary hypertension develops secondarily, signs of right heart failure such as jugular venous distension, right ventricular gallop, and leg edema accompany. The joint involvement signs of RA (finger joint swelling, deformity, morning stiffness) and systemic inflammatory signs (subcutaneous nodules, bunions) must be evaluated together. On pulmonary function tests, decreased diffusing capacity (DLCO) appears before structural changes, and a restrictive pattern with decreased FVC and TLC is typical. In the bronchiolitis-predominant type, a mixed pattern with a decreased FEV1/FVC ratio is observed.

8. Screening

Regular pulmonary function testing and HRCT screening are recommended for RA patients with respiratory symptoms (exertional dyspnea, chronic cough) or in the high-risk group for extra-articular manifestations (seropositive, male, smokers). Pulmonary function tests (PFT) include FVC, FEV1, TLC, and DLCO, and DLCO is the most sensitive indicator of early ILD changes. HRCT is the standard imaging test to assess the presence of ILD, the radiographic pattern (UIP, NSIP, OP, etc.), and the distribution and extent of lesions. The 6-minute walk test (6MWT) is used to assess functional exercise capacity and the degree of oxygen desaturation. Serum KL-6 (Krebs von den Lungen-6) and SP-D (surfactant protein D) are serum biomarkers of lung epithelial injury and are used as diagnostic aids and for monitoring disease activity in RA-ILD. Echocardiography is performed to assess secondary pulmonary hypertension and confirm right ventricular function. Anti-CCP antibody and RF titers are referred to for ILD risk classification.

9. Diagnosis

The diagnosis of RA-ILD is established when ILD is confirmed in a patient who meets the RA diagnostic criteria (ACR/EULAR 2010) and other causes (after excluding infection and drug toxicity) are ruled out. HRCT is key to distinguishing the UIP pattern (reticular opacities, honeycombing, basal predominant distribution, traction bronchiectasis) from the NSIP pattern (ground-glass opacity predominant, basal distribution, honeycombing rare). Bronchoalveolar lavage (BAL) is used to differentiate infection and eosinophilic lung disease and to confirm lymphocytosis in OP. Surgical lung biopsy (VATS) is performed when HRCT findings are atypical or when confirming the histologic pattern is essential to treatment decisions, and is decided through multidisciplinary discussion (MDD). MTX-induced pulmonary toxicity is a clinical diagnosis, based on onset within weeks to months after starting MTX, BAL lymphocytosis, ground-glass opacity with basal distribution on HRCT, and improvement after MTX discontinuation. The ACR 2023 RA-ILD management guideline recommends a multidisciplinary approach (rheumatology, pulmonology, radiology, pathology) as the basis of diagnosis.

10. Treatment

RA-ILD treatment consists of two pillars: control of underlying RA activity and suppression of ILD progression. MTX is recommended to be used cautiously or avoided in patients with confirmed ILD, and substitution with leflunomide is considered. The efficacy and safety of TNF inhibitors in RA-ILD are unclear, and cases of ILD worsening in some patients have been reported, so caution is needed. Abatacept has a relatively good safety profile in RA-ILD and is one of the preferred biologic agents. Rituximab has shown a lung function–stabilizing effect in NSIP-pattern RA-ILD and is used as an option. The antifibrotic agent nintedanib is increasingly used in progressive fibrosing RA-ILD based on the 2023 INBUILD study, and has been confirmed to significantly reduce the rate of FVC decline. In acute exacerbation, high-dose steroids (methylprednisolone pulse) are given and BAL is performed to differentiate infection. Lung transplantation may be considered in end-stage RA-ILD. Smoking cessation is strongly recommended for all patients, and pulmonary rehabilitation contributes to improved exercise capacity and quality of life.

11. Prognosis

RA-ILD is an important complication that raises the overall mortality risk of RA patients by about 2–4 times. Histologic pattern is the most important determinant of prognosis; median survival of the UIP pattern is about 3–5 years after diagnosis, whereas that of the NSIP pattern is significantly longer at about 7–9 years. FVC below 70% of predicted, DLCO below 40%, and oxygen desaturation during the 6MWT are poor prognostic factors. An absolute decline in FVC of 10% or more within 1 year after diagnosis is an independent predictor of mortality risk. Acute exacerbation of ILD has an extremely poor in-hospital mortality of 50% or more, and even survivors experience rapid worsening of lung function. The 5-year survival of RA-ILD patients after lung transplantation is about 50–60%, similar to outcomes after transplantation for idiopathic pulmonary fibrosis. Early detection and multidisciplinary management, smoking cessation, and antifibrotic treatment for progressive fibrosis are important for improving survival.

12. Prevention

Primary prevention of RA-ILD focuses mainly on eliminating smoking, a modifiable risk factor. Smoking cessation is the most effective intervention for reducing not only the clinical course of RA itself but also the risk of developing ILD. Early and thorough control of RA activity according to a treat-to-target (T2T) strategy can reduce accumulation of lung damage due to systemic inflammation. When respiratory symptoms occur during MTX use, MTX should be stopped immediately and lung evaluation performed. Regular PFT and HRCT monitoring (at intervals of at least 1–2 years in seropositive RA, smoking history, older age, and male patients) enables early detection. Oral hygiene management and periodic treatment of periodontal disease may indirectly prevent triggering of pulmonary autoimmune responses by oral pathogens. Pneumococcal and influenza vaccination reduces the risk of infection-triggered ILD exacerbation. Whether early administration of antifibrotic agents such as nintedanib is advantageous for suppressing ILD progression will be determined by future prospective studies.

13. References

1. Bongartz T, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583-91.

2. Flaherty KR, et al. Nintedanib in progressive fibrosing interstitial lung diseases (INBUILD). N Engl J Med. 2019;381(18):1718-27.

3. Doyle TJ, et al. Interstitial lung disease in rheumatoid arthritis: concordance between HRCT patterns and histology. J Rheumatol. 2012;39(12):2439-47.

4. Sparks JA, et al. Rheumatoid arthritis-associated interstitial lung disease: risk factors and clinical outcomes. Rheum Dis Clin North Am. 2021;47(2):283-299.

5. Kelly CA, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics. Rheumatology. 2014;53(9):1676-82.

6. Kim EJ, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322-8.

7. Nakashita T, et al. KL-6 and surfactant protein D as serum biomarkers for interstitial lung disease in RA. Mod Rheumatol. 2018;28(5):851-8.

8. Fragoulis GE, et al. Methotrexate and interstitial lung disease: controversies and questions. Arthritis Rheumatol. 2019;71(9):1413-23.

9. Oldham JM, et al. MUC5B promoter variant and RA-ILD. Am J Respir Crit Care Med. 2017;195(11):1509-11.

10. Johnson SR, et al. ACR 2023 Guideline for the Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2024;76(1):1-20.